Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD3161 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 150 μL intradermal injection of 1 μmol/L AZD3161 |
| 2 | EXPERIMENTAL | 150 μL intradermal injection of 6 μmol/L AZD3161 |
| 3 | EXPERIMENTAL | 150 μL intradermal injection of 30 μmol/L AZD3161 |
| 4 | ACTIVE_COMPARATOR | 150 μL intradermal injection of 10 mg/mL Lidocaine |
| 5 | PLACEBO_COMPARATOR | 150 μL intradermal injection of AZD3161 placebo |
| Name | Type | Description |
|---|---|---|
| AZD3161 | DRUG | Single dose, intradermal injection |
| Lidocaine | DRUG | Single dose, intradermal injection |
| AZD3161 Placebo | DRUG | - |
Inclusion Criteria: * Healthy Caucasian male and female volunteers aged 18 to 55 years inclusive with suitable veins for venepuncture * The subject belongs to skin type II or III according to Fitzpatrick skin type scale * Females must have a negative pregnancy test at screening and at admission, mu...
AZD3161 is an investigational small molecule developed by AstraZeneca PLC for peripheral neuropathic pain. It has been studied in a Phase 1 clinical trial in healthy volunteers. AZD3161 is designed to block SCN9A, a sodium channel target. It has not been approved for any indication and remains in clinical development.
AZD3161 is being developed for peripheral neuropathic pain. It has also been studied in the context of nociceptive pain. The drug is investigational and has not been approved for any use. Its clinical evaluation has been limited to a Phase 1 trial in healthy volunteers.
AZD3161 targets SCN9A, a sodium channel. It acts as a blocker of this target. SCN9A is associated with pain signaling, and blocking it is the intended mechanism for treating peripheral neuropathic pain. The drug is a small molecule developed by AstraZeneca.
AZD3161 is being developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the clinical program for this investigational small molecule. The company is responsible for its development in peripheral neuropathic pain.
AZD3161 is in Phase 1 clinical development. It has completed one Phase 1 trial and has no active trials. The drug is investigational and has not been approved by the FDA or any regulatory agency for any indication.
AZD3161 has been studied in one completed Phase 1 trial, NCT01240148. The trial enrolled 26 healthy volunteers in the United Kingdom and evaluated the effect of AZD3161 injected intradermally on quantitative sensory testing variables in normal and ultraviolet-C exposed skin. It was randomized, double-blind, and placebo-controlled.